Repligen (NASDAQ:RGEN) Updates FY 2024 Earnings Guidance

Repligen (NASDAQ:RGEN) updated its FY 2024 earnings guidance on Tuesday. The company provided earnings per share guidance of 1.500-1.580 for the period, compared to the consensus earnings per share estimate of 1.430. The company issued revenue guidance of $630.0 million-$639.0 million. Repligen also updated its FY24 guidance to $1.50-1.58 EPS.

Wall Street Analyst Weigh In

RGEN has been the subject of several research reports. Royal Bank of Canada reissued an “outperform” rating and issued a $205.00 target price on shares of Repligen in a report on Thursday, September 26th. JPMorgan Chase & Co. increased their price objective on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a report on Wednesday, July 31st. Wells Fargo & Company started coverage on shares of Repligen in a research report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 target price on the stock. Stephens reiterated an “overweight” rating and issued a $170.00 price target on shares of Repligen in a research report on Tuesday, July 30th. Finally, Benchmark reissued a “hold” rating on shares of Repligen in a research report on Monday, August 5th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $190.25.

Repligen Stock Down 0.8 %

RGEN stock opened at $139.51 on Tuesday. The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26. The company’s 50-day moving average price is $141.56 and its 200 day moving average price is $145.05. Repligen has a 52 week low of $113.50 and a 52 week high of $211.13. The company has a market cap of $7.81 billion, a P/E ratio of -3,487.75, a P/E/G ratio of 4.04 and a beta of 0.96.

Insider Transactions at Repligen

In related news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the sale, the director now owns 139,840 shares of the company’s stock, valued at $20,328,540.80. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 1.20% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.